Detailed comparison on parameters like NAV | Returns | Risk | Rating | Analysis
Risk | Very High | Very High |
Rating | 1.0 | 5.0 |
Min SIP Amount | ₹200 | ₹100 |
Expense Ratio | 2.45 | 1.91 |
NAV | ₹27.35 | ₹36.58 |
Fund Started | 08 Feb 2019 | 25 Jun 2018 |
Fund Size | ₹84.18 Cr | ₹5295.32 Cr |
Exit Load | Exit Load for units in excess of 12% of the investment,1% will be charged for redemption within 90 days. | Exit load of 1% if redeemed within 15 days. |
Risk
Rating
Min SIP Amount
Expense Ratio
NAV
Fund Started
Fund Size
Exit Load
1 Year | 14.12% | 20.33% |
3 Year | 17.13% | 24.92% |
5 Year | 16.70% | 24.75% |
1 Year
3 Year
5 Year
Equity | 98.03% | 98.28% |
Cash | 1.97% | 1.72% |
Equity
Cash
Top 10 Holdings |
|
|
Top 10 Holdings
Name | Assets |
---|---|
Sun Pharmaceutical Industries Ltd. | 10.03% |
Piramal Pharma Ltd. | 5.90% |
Torrent Pharmaceuticals Ltd. | 5.29% |
Artemis Medicare Services Ltd. | 5.09% |
Glenmark Pharmaceuticals Ltd. | 4.59% |
Cipla Ltd. | 4.26% |
Divi's Laboratories Ltd. | 3.93% |
Alkem Laboratories Ltd. | 3.78% |
Abbott India Ltd. | 3.71% |
Syngene International Ltd. | 3.57% |
Name | Assets |
---|---|
Sun Pharmaceutical Industries Ltd. | 13.50% |
Dr. Reddy's Laboratories Ltd. | 8.95% |
Cipla Ltd. | 8.85% |
Divi's Laboratories Ltd. | 6.71% |
Aurobindo Pharma Ltd. | 5.30% |
Lupin Ltd. | 4.73% |
Alkem Laboratories Ltd. | 4.42% |
Mankind Pharma Ltd. | 3.50% |
Gland Pharma Ltd. | 3.39% |
Zydus Lifesciences Ltd. | 3.10% |
Name | Karan Doshi | Dharmesh Kakkad |
Start Date | 31 Jul 2023 | 23 Feb 2021 |
Name
Start Date
Description | The Scheme seeks to achieve long term capital appreciation by predominantly investing in equity and equity related instruments of companies engaged in Healthcare and Allied sectors. | The scheme seeks to generate long-term capital appreciation by creating a portfolio that is invested in equity and equity related securities of pharma, healthcare, hospitals, diagnostics, wellness and allied companies. |
Launch Date | 08 Feb 2019 | 25 Jun 2018 |
Description
Launch Date